A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants

Blood Coagulation and Fibrinolysis

Volumn 25, Issue 8, 2014, Pages 812-815

  Carrier, Marc ^a   Kimpton, Miriam ^a   Wells, Philip S ^a   Langlois, Nicole ^a   Kherani, Shemina ^a   Le Gal, Gregoire ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Acenocoumarol; Venous thrombosis; Warfarin

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ADULT; AGED; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; GENERAL PRACTITIONER; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT IDENTIFICATION; PATIENT MONITORING; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; THERAPEUTIC RANGE; THERAPY EFFECT; TIME TO TREATMENT; TREATMENT DURATION; VALIDATION STUDY; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; OUTPATIENT; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; OUTPATIENTS; ROC CURVE; VENOUS THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 84927690693     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000148     Document Type: Article

References (21)

1. Einstein Investigators Bauersachs R, Berkowitz R, Berkowitz SD, Brenner B, Buller HR, et al.. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 20120;363:2499-2510.
2. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-1297.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
6. Ansell JE, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: ACCP evidence-basedclinicalpracticeguidelines. Chest 2008;133:160S-198S.
7. Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-intherapeutic range. J Thromb Thrombolysis 2003;15:213-216.
8. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-17.
9. Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004;126:1938-1945.
10. Oake N, Fergusson DA, Forster AJ, van Walraven C. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 2007;176:1589-1594.
11. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ 2008;179:235-244.
12. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-983.
13. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-239.
14. Pengo V, Pegoraro C, Cucchini U, Iliceto S. Worldwide managementoforal anticoagulant therapy: The ISAM Study. J Thromb Thrombolysis 2006;21:73-77.
15. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control. A systematic review and metaregression. Chest 2006;129:1155-1166.
16. Wilson SJ, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton E, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 2003;169:293-298.
17. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis 2000;9:283-292.
18. Kamel H, Easton JD, Johnston SC, Kim AS. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology 2012;79:1428-1434.
19. Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, etal. Costeffectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 2012;98:573-578.
20. Langkilde LK, Bergholdt AM, Overgaard M. Cost-effectivenessofdabigatran etexilate for stroke prevention in nonvalvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark. J Med Econ 2012;15:695-703.
21. Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011;105:908-919.